These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30504201)

  • 21. The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis.
    Hasson C; Veling L; Rico J; Mhaskar R
    Medicine (Baltimore); 2019 Dec; 98(51):e18225. PubMed ID: 31860969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxyurea reduces infections in children with sickle cell anemia in Uganda.
    Namazzi R; Bond C; Conroy AL; Datta D; Tagoola A; Goings MJ; Jang JH; Ware RE; Opoka R; John CC
    Blood; 2024 Apr; 143(14):1425-1428. PubMed ID: 38169476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
    Zahr RS; Hankins JS; Kang G; Li C; Wang WC; Lebensburger J; Estepp JH
    Am J Hematol; 2019 Jan; 94(1):E27-E29. PubMed ID: 30359463
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term use of hydroxyurea for sickle cell anemia.
    Hagar W
    JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424
    [No Abstract]   [Full Text] [Related]  

  • 26. MRI abnormalities in infants with sickle cell anemia-indication for preemptive therapy?
    Ozsahin H
    Pediatr Blood Cancer; 2008 Nov; 51(5):573-4. PubMed ID: 18623220
    [No Abstract]   [Full Text] [Related]  

  • 27. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
    Galadanci NA; Abdullahi SU; Tabari MA; Abubakar S; Belonwu R; Salihu A; Neville K; Kirkham F; Inusa B; Shyr Y; Phillips S; Kassim AA; Jordan LC; Aliyu MH; Covert BV; DeBaun MR
    Pediatr Blood Cancer; 2015 Mar; 62(3):395-401. PubMed ID: 25399822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort.
    Opoka RO; Hume HA; Latham TS; Lane A; Williams O; Tymon J; Nakafeero M; Kasirye P; Ndugwa CM; John CC; Ware RE
    Haematologica; 2020 Jun; 105(6):e272-e275. PubMed ID: 31649130
    [No Abstract]   [Full Text] [Related]  

  • 29. Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease.
    Knight LMJ; Tanabe P; Blewer AL; Goodrich J; King AA; Reuter-Rice K; Crego N
    Pediatr Blood Cancer; 2024 Jul; 71(7):e31017. PubMed ID: 38706206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE-PART II.
    Debaun MR
    Trans Am Clin Climatol Assoc; 2022; 132():236-248. PubMed ID: 36196180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy.
    Ballas SK; Martinez U; Savage M
    Hemoglobin; 2014; 38(5):373-5. PubMed ID: 25238042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
    Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia.
    Taylor JG; Darbari DS; Maric I; McIver Z; Arthur DC
    Ann Intern Med; 2011 Nov; 155(10):722-4. PubMed ID: 22084346
    [No Abstract]   [Full Text] [Related]  

  • 34. Hydroxyurea marketed for sickle cell anemia.
    Am J Health Syst Pharm; 1998 May; 55(9):875. PubMed ID: 9588244
    [No Abstract]   [Full Text] [Related]  

  • 35. Hydroxyurea for sickle cell anemia.
    Naina HV; Harris S
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract]   [Full Text] [Related]  

  • 36. Medical Neglect by Underprescription and Underutilization of Hydroxyurea in Children with Sickle Cell Disease.
    Rana S
    South Med J; 2016 Sep; 109(9):503-5. PubMed ID: 27598349
    [No Abstract]   [Full Text] [Related]  

  • 37. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.
    Stettler N; McKiernan CM; Melin CQ; Adejoro OO; Walczak NB
    JAMA; 2015 Apr; 313(16):1671-2. PubMed ID: 25919532
    [No Abstract]   [Full Text] [Related]  

  • 38. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
    Ritho J; Liu H; Hartzema AG; Lottenberg R
    Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term use of hydroxyurea for sickle cell anemia.
    Lee DA; Mueller BU
    JAMA; 2003 Aug; 290(6):753-4; author reply 754. PubMed ID: 12915425
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment adherence in patients with sickle cell anemia.
    Drotar D
    J Pediatr; 2010 Mar; 156(3):350-1. PubMed ID: 20056235
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.